

Kim H Orchard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8271053/publications.pdf>

Version: 2024-02-01

55
papers

3,934
citations

249298

26
h-index

206121

51
g-index

56
all docs

56
docs citations

56
times ranked

6528
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of COVID-19 on related donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	2
2	SARS-CoV-2 screening for asymptomatic health care workers in UK stem cell transplant units. <i>British Journal of Haematology</i> , 2021, 192, e37-e38.	1.2	1
3	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. <i>Leukemia</i> , 2021, 35, 2885-2894.	3.3	153
4	Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting. <i>Blood Advances</i> , 2021, 5, 4500-4503.	2.5	6
5	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIF). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
6	Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia. <i>Cancers</i> , 2020, 12, 2769.	1.7	6
7	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
8	New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 867-877.	2.0	3
9	Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 500-512.	1.2	4
10	Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 134.	1.0	6
11	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. <i>British Journal of Haematology</i> , 2019, 185, 656-669.	1.2	53
12	Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. <i>British Journal of Haematology</i> , 2019, 185, 89-92.	1.2	28
13	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 778-785.	2.0	21
14	Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 3853-3866.	0.8	13
15	Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 203-203.	0.6	0
16	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	512
17	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. <i>PLoS ONE</i> , 2015, 10, e0140483.	1.1	13
18	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1021-1032.	2.0	27

#	ARTICLE	IF	CITATIONS
19	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. <i>Brain</i> , 2015, 138, 2847-2858.	3.7	128
20	Biosimilar G-CSF Based Mobilization of Peripheral Blood Hematopoietic Stem Cells for Autologous and Allogeneic Stem Cell Transplantation. <i>Theranostics</i> , 2014, 4, 280-289.	4.6	42
21	EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. <i>Bone Marrow Transplantation</i> , 2014, 49, 280-286.	1.3	86
22	Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. <i>British Journal of Haematology</i> , 2013, 162, 107-111.	1.2	50
23	Mumps virus encephalomyelitis in a 19-year old male patient with an undefined severe combined immunodeficiency post-haematopoietic bone marrow transplantation: A rare fatal complication. <i>Journal of Clinical Virology</i> , 2013, 57, 165-168.	1.6	4
24	Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. <i>New England Journal of Medicine</i> , 2013, 369, 2391-2405.	13.9	1,556
25	Biosimilar G-CSF Based Mobilization Of Peripheral Blood Hematopoietic Stem Cells For Autologous and Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5444-5444.	0.6	1
26	Early Experience with Clofarabine Pre-Conditioning Prior to Full Intensity or Reduced Toxicity Allogeneic Stem Cell Transplantation: A Promising New Therapy for the Treatment of Refractory Acute Leukaemia. <i>Blood</i> , 2012, 120, 4511-4511.	0.6	1
27	Immune Reconstitution Following the Use of Targeted Radiotherapy for Reduced Intensity Conditioning in Allogeneic Stem Cell Transplantation: A Single Centre Experience. <i>Blood</i> , 2012, 120, 4489-4489.	0.6	0
28	Development and validation of the ⁵⁷ Co assay for determining the ligand to antibody ratio in bifunctional chelate/antibody conjugates for use in radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 2011, 38, 1103-1110.	0.3	3
29	Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma. <i>European Journal of Haematology</i> , 2011, 87, 554-555.	1.1	5
30	Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 757-769.	2.0	26
31	Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. <i>Bone Marrow Transplantation</i> , 2011, 46, 330-337.	1.3	104
32	CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?. <i>British Journal of Haematology</i> , 2010, 149, 795-796.	1.2	17
33	Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1419-1427.	2.0	93
34	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. <i>Haematologica</i> , 2009, 94, 1024-1028.	1.7	47
35	Frequent upregulation of MYC in plasma cell leukemia. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 624-636.	1.5	65
36	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. <i>Haematologica</i> , 2009, 94, 1708-1713.	1.7	68

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcomes of Myeloablation and Autologous Transplantation of Relapsed Acute Myeloid Leukemia in Second Remission: A British Society of Blood and Marrow Transplantation Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1310-1317.	2.0	22
38	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. <i>Leukemia</i> , 2006, 20, 1610-1617.	3.3	141
39	A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.. <i>Blood</i> , 2006, 108, 3002-3002.	0.6	0
40	Selective Apoptotic Killing of Malignant Hemopoietic Cells by Antibody-Targeted Delivery of an Amphipathic Peptide. <i>Cancer Research</i> , 2005, 65, 2373-2377.	0.4	60
41	Targeted Radiotherapy in the Conditioning Prior to Haematopoietic Stem Cell Transplantation: Results of a Phase I Radiation Dose Escalation Study Using Yttrium-90-Labelled Anti-CD66 Monoclonal Antibody Demonstrating High BM Uptake of Radiation.. <i>Blood</i> , 2005, 106, 2189-2189.	0.6	12
42	CD66 Expression on Malignant and Normal Plasma Cells: A Potential Target for Therapy.. <i>Blood</i> , 2005, 106, 5073-5073.	0.6	5
43	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. <i>Blood</i> , 2004, 104, 4875-4875.	0.6	0
44	Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results. <i>British Journal of Haematology</i> , 2003, 120, 944-952.	1.2	32
45	Bone marrow transplants. <i>BMJ: British Medical Journal</i> , 2002, 325, 348-349.	2.4	1
46	Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. <i>British Journal of Haematology</i> , 2002, 117, 133-135.	1.2	54
47	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 2002, 117, 427-435.	1.2	65
48	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. <i>Bone Marrow Transplantation</i> , 1998, 21, 1055-1061.	1.3	67
49	Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant. <i>British Journal of Haematology</i> , 1998, 100, 561-563.	1.2	35
50	Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1996, 94, 694-698.	1.2	5
51	An EMSA-based method for determining the molecular weight of a protein - DNA complex. <i>Nucleic Acids Research</i> , 1993, 21, 3335-3336.	6.5	75
52	Characterization of a novel T lymphocyte protein which binds to a site related to steroid/thyroid hormone receptor response elements in the negative regulatory sequence of the human immunodeficiency virus long terminal repeat. <i>Nucleic Acids Research</i> , 1992, 20, 5429-5434.	6.5	18
53	A T-cell protein which recognizes a palindromic DNA sequence in the negative regulatory element of the HIV-1 long terminal repeat with homology to steroid/thyroid hormone receptor binding sites. <i>Biochemical Society Transactions</i> , 1990, 18, 555-556.	1.6	1
54	HLA-DA monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cell. <i>British Journal of Haematology</i> , 1982, 52, 411-420.	1.2	29

#	ARTICLE	IF	CITATIONS
55	Circulating Granulocytic and Erythroid Progenitor Cells in Chronic Granulocytic Leukaemia. British Journal of Haematology, 1980, 46, 7-13.	1.2	73